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https://doi.org/10.1016/j.celrep.2019.03.009SUMMARY
The NADPH-dependent oxidase NOX2 is an impor-
tant effector of immune cell function, and its activity
has been linked to oncogenic signaling. Here, we
describe a role for NOX2 in leukemia-initiating stem
cell populations (LSCs). In a murine model of leuke-
mia, suppression of NOX2 impaired coremetabolism,
attenuated disease development, and depleted func-
tionally defined LSCs. Transcriptional analysis of
purified LSCs revealed that deficiency of NOX2 col-
lapses the self-renewal program and activates in-
flammatory and myeloid-differentiation-associated
programs. Downstream of NOX2, we identified the
forkhead transcription factor FOXC1 as a mediator
of the phenotype. Notably, suppression of NOX2
or FOXC1 led to marked differentiation of leukemic
blasts. In xenotransplantation models of primary
human myeloid leukemia, suppression of either
NOX2 or FOXC1 significantly attenuated disease
development. Collectively, these findings position
NOX2 as a critical regulator of malignant hematopoi-
esis and highlight the clinical potential of inhibiting
NOX2 as a means to target LSCs.
INTRODUCTION
Careful regulation of the balance between self-renewal and dif-
ferentiation of hematopoietic stem cells (HSCs) is critical to
ensure the proper function of the blood-forming system (Seita
and Weissman, 2010). Subversion of molecular mechanisms
that regulate these processes leads to defective immune func-
tions and is often causally linked to the development of leukemia
(He et al., 2009; Moran-Crusio et al., 2011; Shao et al., 2011). The
ability to properly control cellular levels of reactive oxygen spe-
cies is one of the best-understood factors that regulate the
biology of stem cells. While excess amounts of reactive oxygen238 Cell Reports 27, 238–254, April 2, 2019 ª 2019 The Authors.
This is an open access article under the CC BY-NC-ND license (http://species (ROS) limit the function of HSCs (Ito et al., 2006; Tothova
et al., 2007) at physiologic levels, ROS are required for the proper
function of stem and progenitor cells (Juntilla et al., 2010; Mori-
moto et al., 2013; Owusu-Ansah and Banerjee, 2009). Therefore,
careful modulation of ROS can play a programmatic role in stem
cell quiescence and differentiation.
NADPH oxidases are a family of multimeric oxido-reductase
enzymes that catalyze the production of superoxide anions.
The holoenzyme is composed of a heterodimeric catalytic
domain containing NOX1–NOX4 (in mice) and p22Phox, the
cytosolic accessory factors (NCF1, NCF2, and NCF4), and the
GTPase RAC proteins (Figure 1A). The hematopoietic version,
NOX2, primarily functions in mature myeloid cells during the res-
piratory burst phase of phagocytosis (Groemping and Rittinger,
2005; Panday et al., 2015). Distinct from this function, NOX2
and its paralogs can produce physiologic levels of ROS and, in
large part owing to their membrane proximal localization, can
also modulate mitogenic signaling events to influence many
aspects of cell biology (Jiang et al., 2011).
A number of studies have uncovered important functional roles
for NADPH oxidases in several types of somatic stem cells. Sper-
matogonial stem cells derived from NOX1 knockout (KO) mice
have aberrancies in their ability to self-renew (Morimoto et al.,
2013). Similarly, NOX2 KO mice have defective neural stem cell
function and impaired adult hippocampal progenitor proliferation
(Dickinson et al., 2011; Le Belle et al., 2011). In the hematopoietic
system, deficiency of either NOX2 or the GTPase RAC proteins
significantly perturbs the normal balance of blood cell production
and limits the self-renewal potential of HSCs (Cancelas et al.,
2005; Roberts et al., 1999; Weisser et al., 2016; Yang et al.,
2007). Moreover, loss-of-function mutations in genes encoding
several subunits of the enzyme are causal for chronic granuloma-
tous disease, a rare inherited immunodeficiency syndrome with
an estimated frequency of 1/200,000 to 1/250,000 newborns
(Giardino et al., 2017). A number of studies aimed at understand-
ing the role of NADPH oxidases in the settings of malignant
tumors have also uncovered some aspects of their function.
In colorectal cancers, RAC1 stimulates ROS production from
NADPH oxidase to facilitate WNT-signaling-driven intestinalcreativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. NOX2 Is Expressed in HSPCs, and Its Deficiency Compromises Steady-State and Regenerative Hematopoiesis
(A) Schematics showing the subunits making up the canonical NADPH oxidase 2 complex.
(B) mRNA expression of all 4 murine paralogs of NADPH oxidase genes in purified LSK cells.
(C) mRNA expression levels of NOX2 in primitive hematopoietic cells. Data are mined from previously reported RNA-seq results (Cabezas-Wallscheid et al., 2014)
(D) mRNA expression of all 4 murine paralogs of NADPH oxidase genes in MPP3 cells.
(E) Frequency of LT-HSCs, MPP1, and MPP4 cells in total live BM from age- and sex-matched WT and NOX2 KO mice. n = 8, two independent experiments.
(F) Frequency of MPP2 and MPP3 cells in total live BM from age- and sex-matched WT and NOX2 KO mice. n = 8, two independent experiments.
(G) Differential cell count on the peripheral blood (PB) of age- and sex-matched WT and NOX2 KO mice. n = 5, representative of 3 independent experiments.
(H) Representative flow cytometric plot showing the composition of PB (left) and the frequency of Gr1/CD11b+myeloid cells in total CD45+ live BM from age- and
sex-matched WT and NOX2 KO mice (right). n = 5.
(I) Frequency of Gr1/CD11b+ myeloid cells in total CD45+ live BM from age- and sex-matched WT and NOX2 KO mice. n = 5.
(J) Competitive transplantation of 500,000 whole BM cells from WT and NOX2 KO mice into irradiated WT recipients. The contribution of donor and competitor
cells in PB is shown.
Bars represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant, unpaired Student’s t test.progenitor cell expansion and transformation (Myant et al., 2013).
In leukemic cells harboring driver mutations in tyrosine kinases,
including BCR-ABL, JAK2, or FLT3ITD, NADPH oxidases primarilypotentiate oncogenic signaling to influence cell growth,migration,
and metabolism (Grauers Wiktorin et al., 2018; Hole et al., 2013;
Marlein et al., 2017; Moloney et al., 2017; Reddy et al., 2011).Cell Reports 27, 238–254, April 2, 2019 239
Moreover, RAC2-deficient BCR-ABL-transformed leukemic cells
appear to have diminished leukemia-initiating potential upon
transplantation (Sengupta et al., 2010). Collectively, these obser-
vations suggest that the NOX2 complex can play important
biological functions in normal and malignant stem cells. Hence,
in the present study using transgenic mice, a genetically defined
murine model of myeloid leukemia, and xenograft studies of
primary human-patient-derived leukemia specimens, we pro-
vide evidence supporting the importance of NOX2 in the patho-
genesis of LSCs in vivo. We further elucidate the mechanisms
operating downstream of NOX2 to regulate the function of
leukemic stem cells.
RESULTS
The NOX2 Complex Is Expressed by Myeloid-Biased
Multipotent Progenitors
To gain insight into the potential role of NOX2 in the normal
biology of the blood-forming system, we initially performed
qRT-PCR-based analyses of purified hematopoietic stem and
progenitor cells (HSPCs) (LSK cells) and measured the mRNA
expression levels of genes encoding all subunits of the complex
(Figure 1A). Compared to all the other paralogs, NOX2 is ex-
pressed at significantly higher levels in HSPCs (Figure 1B).
Importantly, all the accessory subunits of the enzyme complex
are also sufficiently expressed (Figure S1A). Since LSKs are a
mixed population composed of long-term self-renewing HSCs
(LT-HSCs) and a number of multipotent progenitors (MPPs) (Pie-
tras et al., 2015; Wilson et al., 2008), we next took advantage of a
previously published genome-wide expression dataset to eval-
uate the relative abundance of multiple subunits of the NOX2
complex in highly purified populations (Cabezas-Wallscheid
et al., 2014). Interestingly, at steady state, NOX2 levels are the
highest in the myeloid-biased MPP2 and/or MPP3 subpopula-
tions compared to LT-HSCs, MPP1s and the lymphoid biased
MPP4 subpopulation (Figure 1C) (Cabezas-Wallscheid et al.,
2014; Pietras et al., 2015) whereas the other subunits of the com-
plex are expressed in nearly all subpopulations examined (Fig-
ure S1B). Furthermore, within the MPP3 compartment, NOX2
is the only paralog expressed (Figure 1D). Combined, these re-
sults support the interpretation that a myeloid-biased subset of
HSPCs possess the full repertoire of NOX2 complex proteins,
and thus, NADPH oxidase activity may have a unique functional
role in these subpopulations.
NOX2-Deficient HSCs Have Myeloid-Biased Output and
Regenerative Defects
To investigate the potential role of NOX2 in normal hematopoie-
sis, we next performed comparative phenotypic characterization
of age- and sex-matched wild-type (WT) and transgenic NOX2-
deficient (NOX2 KO) mice (Figure S1C) (Pollock et al., 1995).
While total marrow cellularity is relatively comparable (Fig-
ure S1D), consistent with previous reports, NOX2 KO mice
have expanded immunophenotypically defined HSPCs (Fig-
ure S1E) (Weisser et al., 2016). Interestingly, within HSPCs,
only the myeloid biased MPP2 and/or MPP3 subsets, where
we observed the highest expression of NOX2, show marked
expansion, while the frequency of LT-HSCs, MPP1s, and240 Cell Reports 27, 238–254, April 2, 2019MPP4s were virtually indistinguishable between the two geno-
types (Figures 1E and 1F). In the peripheral blood (PB), differen-
tial cell counts revealed that NOX2 KO mice generally produce a
larger number of leukocytes (Figure 1G). Most notably, much of
the increase is due to the preferential overproduction of myeloid
cells (Figures 1G, 1H, and S1F). In line with these findings, the
bone marrow (BM) representation of CD11b- and MAC1-
expressing myeloid cells was also increased in NOX2 KO mice
(Figure 1I). Collectively, these findings suggest that at steady
state, NOX2 functions to influence the magnitude of myelopoie-
sis starting at the earliest stage of multilineage differentiation.
Given the observation that hematopoiesis is considerably per-
turbed in NOX2-deficient mice, we examined the extent to which
HSC function is compromised in the absence of NOX2 by per-
forming competitive repopulation assays. Analysis of engrafted
mice revealed that NOX2-deficient HSCs are significantly limited
in their ability to contribute to all lineages of hematopoiesis (Fig-
ures 1J and S1G). Moreover, analysis of BM showed that NOX2
KOmice also fail to regenerate and contribute to the LT-HSC and
MPP compartments (Figure S1H). Taken together, these results
strongly suggest that NOX2 controls the self-renewal potential of
HSCs in the context of transplantation-induced regenerative
stress.
Depletion of the NOX2 Complex Attenuates
Leukemogenesis In Vivo
Leukemias often arise by the oncogenic transformation of
normal HSPCs through corruption of self-renewal, proliferation,
and differentiation mechanisms. Given our observations in
normal hematopoietic cells that NOX2 deficiency perturbs mye-
lopoiesis and limits self-renewal, we hypothesized that NOX2
could have a functional role in the biology of malignant myeloid
leukemia-initiating stem cell populations (LSCs). To test the
hypothesis, we utilized a genetically defined murine model of
aggressive blast crisis myeloid leukemia induced by retroviral
vectors carrying two potent oncogenic chromosomal transloca-
tions, BCR-ABL and NUP98-HOXA9, each independently
marked by the fluorescent proteins GFP and YFP, respectively
(Figure 2A) (Dash et al., 2002). In this model, we have previously
characterized the immunophenotype (Sca1+ Lineage) and
several functional aspects of the LSC that drive and sustain the
disease (Ashton et al., 2012; Neering et al., 2007; Ye et al.,
2016). Using qRT-PCR-based analyses, we initially determined
the relative expression levels of NADPH oxidase genes. Consis-
tent with the normal HSPCs, the results showed that NOX2 is by
far the predominant paralog expressed in leukemic stem cells
(Figure S2A).
Next, to investigate the potential role of NOX2 in leukemia initi-
ation and development, we transduced immature bone-marrow-
derived hematopoietic cells from age- and sex-matchedWT and
NOX2 KO mice with our retroviral constructs and transplanted
them into syngeneic recipient mice. BM cells from both geno-
types were equally and efficiently transformed by the oncogenes
(Figure S2B). Intriguingly, recipients of NOX2 KO leukemia
have relatively lower disease burden in the BM and spleen
compared to WT controls (Figures 2B, 2C, and S2C). Moreover,
re-transplantation of purified bone-marrow-derived primary
leukemia cells into secondary recipients resulted in further
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Figure 2. Deficiency of the NOX2 Complex Attenuates Leukemogenesis In Vivo
(A) Schematics showing retroviral oncogenesis model used to generate murine leukemia.
(B) Representative flow cytometric plot showing frequency of leukemic cells in the BM of recipients of primary WT and NOX2 KO leukemia.
(C) Frequency of leukemic cells in the BM of primary recipients of leukemic cells. n = 9.
(D) Frequency of leukemic cells in the BM of secondary recipients. WT, n = 11; KO, n = 12.
(E) Cytospin preparation of PB (left) and H&E staining of sections of spleen (middle) and liver (right) from secondary recipients of WT and NOX2 KO leukemia.
Arrows show splenic nodules that are relatively better preserved in KO leukemias. Additional supporting data are presented in Figures S2E and S2F. Scale bars
represent 50 mm for PB and 200 mm for spleen and liver.
(F) Limiting dilution analysis showing the frequency of leukemia-initiating stem cell populations from secondary WT or NOX2 KO leukemic cells.
(G) shRNA-mediated suppression of mRNA expression of the p22Phox subunit of NOX2.
(H) Representative flow cytometric plot showing BMdisease burden of leukemic cells in recipients of non-targeting shRNA (shNT) and shp22Phox leukemic cells.
(I) Frequency of leukemic cells in the BM of recipients of shNT and shp22Phox leukemic cells. n = 10.
(J) The weight of spleen extracted from recipients of shNT or shp22Phox leukemia cells (left) and representative images (right).
Bars represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant, unpaired Student’s t test.
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attenuation of disease development (Figures 2D and S2D).
Cytospin preparations and histopathologic analysis also re-
vealed reduced prevalence of leukemic cells in the PB and rela-
tively subdued invasion of extramedullary tissues (Figures 2E,
S2E, and S2F). Consistent with these findings, we observed
marked extension of survival in mice engrafted with NOX2 KO
leukemia, with the disease latency being significantly longer in
recipients of secondary leukemia (Figure S2G). Finally, to eval-
uate the functional impact of NOX2 deficiency at the level of
LSCs, we performed a limiting dilution analysis by transplanting
a graded dose of LSCs into recipient mice. Our results revealed
that the frequency of functionally defined leukemia stem cells is
substantially lower in NOX2 KO leukemia cells relative to controls
(Figure 2F).
Since NOX2 is a multimeric complex, we next wanted to eval-
uate the broader requirement of the entire enzymatic complex.
To this end, we investigated the role of p22Phox, a critical sub-
unit of the complex that dimerizes with NOX2 to form the catalyt-
ically active enzyme. Using lentiviral short hairpin RNA (shRNA)
constructs, we efficiently reduced the expression of p22Phox
in primary BM-derivedWT leukemia cells (Figure 2G).We then in-
jected control and p22Phox knockdown (KD) cells into second-
ary hosts. Consistent with our findings using NOX2 KO leukemia,
suppression of p22Phox also diminished the growth of leukemic
cells in both the BM and spleen of transplanted mice (Figures
2H–2J). Taken together, these findings strongly argue that the
NOX2 complex is expressed in LSCs and plays an important
functional role in the engraftment, self-renewal, and proliferation
of leukemic stem cells.
Deficiency of NOX2 Reduces Basal ROS and Impairs
Core Metabolism
Since NOX2 produces reactive oxygen species as end products
of catalysis, we measured the relative levels of ROS in leukemic
explants from the BM of secondary recipient mice using the
redox-sensitive fluorescent probe CellROX. We observe that
NOX2 KO LSCs, as well as lineage-marker-expressing bulk
leukemic cells, exist in a relatively reduced state (Figures 3A
and 3B). Interestingly, non-leukemic cells co-inhabiting the BM
niche also displayed reduced ROS, suggesting that in the
absence of NOX2 the leukemic microenvironment is also less
oxidized (Figure 3C). To directly test whether NOX2 contributes
to physiologic levels of ROS, we next antagonized its enzymatic
activity with small-molecule inhibitors (Altenho¨fer et al., 2015).
Inhibition of NOX2 reduced intracellular ROS levels relative to
controls, suggesting that NOX2 partially contributes to the over-
all redox state of leukemic cells (Figures S3A and S3B). Given
these observations, we decided to investigate whether general
oxidative-stress-associated mechanisms contribute to the phe-
notypes observed in NOX2 KO leukemia cells. To this end, we
treated a cohort of mice engrafted withWT leukemia with the uni-
versal ROS scavenger N-acetyl cysteine (NAC) throughout the
course of disease development (Figure S3C). NAC treatment
marginally reduced ROS levels in the BM of recipient mice (Fig-
ure S3D). Importantly however, we did not observe a significant
attenuation of disease progression in vivo (Figure S3E), suggest-
ing that overt oxidative-stress-linked mechanisms have a limited
effect on leukemogenesis in this model.242 Cell Reports 27, 238–254, April 2, 2019Since the substrates for NOX2, namely molecular oxygen and
the cofactor NADPH, are critical components of several cellular
metabolic pathways, we next investigated the impact of NOX2
deficiency in the core metabolism of leukemia cells. Mitochon-
drial oxygen consumption and glycolytic flux measurements
were carried out on BM-derived lineage-negative WT and
NOX2KO leukemia cells. Interestingly, relatively reduced oxygen
consumption and significantly diminished maximal mitochon-
drial respiratory capacity were observed in NOX2 KO leukemia
cells (Figures 3D and 3E). Moreover, measurement of the rate
of extracellular acidification (ECAR) as an indicator of glycolytic
potential revealed that NOX2 KO leukemia cells utilize glycolysis
to a surprisingly limited degree (Figure 3F). Notably, in NOX2 KO
leukemia cells, both mitochondrial and glycolytic metabolism
were relatively less dynamic, as there was a blunted response
to chemical perturbation of the electron transport chain or
proton conductance across mitochondrial membrane. Com-
bined, these findings suggest that there is a marked impairment
of core metabolic pathways in leukemic cells in the absence
of NOX2.
To gain a better insight into the metabolic reprograming
induced by lack of NOX2, we performed global metabolic
profiling using ultra-high-pressure liquid chromatography-
coupled mass spectrometry (UHPLC-MS). Principal-component
analysis showed that WT and NOX2 KO leukemic cells segre-
gated based on their metabolic profiles (Figure S3F), indicating
potentially distinct modes of metabolism. Consistent with their
reduced state, NOX2 KO leukemia cells contained elevated
levels of the antioxidants ascorbate, glutathione, and the gluta-
thione precursor dipeptide cysteine-glycine (Figure S3G). Most
importantly, a closer examination of the identity of the differen-
tially abundant metabolites revealed that NOX2 KO leukemic
cells contain high levels of carnitine-conjugated short- and
intermediate-length free fatty acids (Figures 3G, 3H, and S3H).
Carnitine conjugation facilitates the activation and transport of
free fatty acids into the mitochondria for oxidation. Thus, we
next measured the relative rate of fatty acid oxidation (FAO)
using tritium-labeled palmitate. The results showed that NOX2
KO leukemia cells have a substantially higher rate of FAO than
WT controls (Figure 3I). In totality, these findings suggest that
depletion of NOX2 rewires key metabolic pathways promoting
the use of fatty acids as mitochondrial fuel and limiting glycolytic
pathways that generate essential metabolites for anabolic reac-
tions that leukemia cells use to grow and proliferate.
Deficiency of NOX2 Abrogates Stem Cell-Associated
Transcriptional Programs
To further understand the potential mechanisms by which NOX2
regulates leukemogenesis, we assessed the impact of NOX2
loss on global transcriptional output. We purified LSCs from
BM explants of secondary recipients and performed RNA
sequencing (RNA-seq) analysis. Unsupervised hierarchical clus-
tering segregated the samples into their respective genotypes
(Figure S4A). To uncover the NOX2-mediated gene expression
changes, we applied stringent statistical criteria to identify a total
of 143 differentially expressed genes, of which 80 were upregu-
lated (log2 fold change > 1.5, p < 0.05) and 63 were downregu-
lated (log2 fold change < 1.5, p < 0.05) in NOX2 KO LSCs
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Figure 3. Suppression of NOX2 Reduces Basal ROS and Impairs Core Metabolism
(A) Representative histogram showing the fluorescence of CellROX within the leukemia-initiating stem cell population (LSC) compartment of leukemic cells (left)
and mean fluorescence intensity of CellROX (right). n = 10.
(B) Mean fluorescence intensity of CellROX in the lineage-positive compartment of leukemic cells. n = 10.
(C)Mean fluorescence intensity of CellROXof theGFP/YFP (GY) non-leukemic cells co-inhabiting the bonemarrowwith eitherWT orNOX2KO leukemia. n = 10.
(D) Relative rate of oxygen consumption in WT and NOX2 KO secondary leukemia cells.
(E) Maximal respiration rate of WT and NOX2 KO leukemia cells.
(F) Extracellular acidification rates (proxy for glycolytic potential) of WT and NOX2 KO leukemic cells.
(D–F) n = 5 technical replicates, representative of 2 independent experiments.
(G)Heatmap showing the relative abundance of themost significantly alteredmetabolites detected inWTandNOX2KO leukemia cells viamass spectrometry. n = 4
technical replicates.
(H) The relative abundance of carnitine-conjugated short-chain free fatty acids from WT and NOX2 KO leukemia cells.
(I) The relative rate of tritium-labeled palmitic acid oxidation inWT and NOX2 KO leukemia cells asmeasured by quantitating the cleavage of radioactive hydrogen
via scintillation counts. n = 4 technical replicates.
Bars represent mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, not significant, unpaired Student’s t test.compared toWT controls (Table S1). Among genes that are high-
ly increased in expression in NOX2 KO LSCs, several of them are
associated with mature myeloid cell function. These include the
myeloid transcription factor CEBPε, a number of proteolytic en-
zymes, including the neutrophil elastase (Elane), and Cathepsin
G (CTSG), Cathepsin S (CTSS), as well as the inflammatoryamplifier proteins S100a8 and S100a9 (Figure 4A). Conversely,
several genes encoding cell adhesion (ITGb3, Tie1, and CD96)
and signaling adaptor molecules (GRB7 and STAP2), as well
as the stem cell associated transcription factor FOXC1 and the
retinol metabolizing dehydrogenase ALDH1a2, were downregu-
lated in NOX2 KO LSCs relative to WT controls (Figure 4A). WeCell Reports 27, 238–254, April 2, 2019 243
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(A) Heatmap shows normalized fragments per kilobase of transcript per million mapped reads (FPKM) values of the most significantly dysregulated genes in
WT and NOX2 KO LSCs. Log2 values of the fold change for the selected up- and downregulated genes are shown as waterfall bar graphs.
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(legend continued on next page)
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validated some of these observations using qRT-PCR-based
analysis of gene expression on LSCs purified from an indepen-
dent cohort ofWT andNOX2KO leukemia aswell as from control
and p22Phox KD leukemic cells (Figures 4B and 4C).
Next, to gain deeper insight into the global genetic changes
that are brought about by the lack of NOX2 in leukemic stem
cells, we performed gene set enrichment analysis (GSEA).
Consistent with our metabolic analysis, we observed depletion
of genes involved in glycolysis and glucose metabolism
and enrichment of fatty-acid-metabolism-associated genes in
NOX2 KO LSCs relative to WT controls (Figures S4B and
S4C). Strikingly, gene expression signatures associated with
both normal HSCs (Chambers et al., 2007) and leukemia stem
cells (Gal et al., 2006) were markedly enriched in WT LSCs rela-
tive to their NOX2 KO counterparts (Figure 4D). Conversely,
genes that are selectively depleted in LSCs (Gal et al., 2006)
as well as a gene set signature of leukocyte differentiation
were highly enriched in NOX2 KO LSCs relative to controls (Fig-
ure 4E). Moreover, we also observed a marked enrichment of
innate immune system related pathways in NOX2 KO LSCs
(Figure S4D). Taken together, the data strongly suggests that
NOX2 plays an important role in maintaining stem cell associ-
ated programs in LSCs and in its absence leukemic cells
display enhanced proclivity to activate transcriptional pro-
grams akin to those employed by functionally specialized
mature myeloid cells.
Deficiency of NOX2 Induces the Differentiation of
Leukemic Cells
Given the loss of stem cell potential and the corresponding in-
duction of myeloid-maturation-related genetic programs, we
next examinedwhether leukemic cells undergo terminal differen-
tiation as a consequence of NOX2 loss. Immunophenotypic
characterization was performed on secondary leukemic ex-
plants from the BM of recipients of WT and NOX2 KO leukemia.
We observed a significant increase in the fraction of leukemic
cells expressing canonical myeloid maturation markers in the
absence of NOX2 relative to controls (Figure 4F). In addition, his-
tologic analysis via May-Gr€unwald-Giemsa staining showed that
NOX2 KO leukemia cells display morphologic characteristics of
myeloid differentiation marked by segmented nuclei, increased
abundance of granular and vacuolar structures, and enlarged
cytoplasms (Figures 4G and S4F). Similar observations were
also made in p22Phox KD leukemia cells relative to controls (Fig-
ures 4H, 4I, and S4G). Therefore, the combined results of our
studies suggest that the NADPH oxidase complex promotes
the extensive self-renewal potential of leukemic stem cells and
underscores an underlying defect in transcriptional programs(E) GSEA showing enrichment of differentiation program (right) and leukemia ste
(F) Representative histogram plot showing the relative expression levels of the my
KO leukemia.
(G) Images showing the morphology of WT and NOX2 KO leukemia cells an
Figure S4F. Scale bars represent 10 mm.
(H) Relative expression of the myeloid-differentiation-associated surface antigen
from BM.
(I) Images showing the morphology of control and p22Phox KD leukemia cells a
Figure S4G.essential for maintaining leukemic stem cells in an undifferenti-
ated state in the absence of NOX2.
NOX2 Controls Inflammatory Signaling Pathways
Next, we focused on cell signaling pathways that are dysregu-
lated in NOX2 KO leukemia cells with the aim of discerning
some of the molecular mechanisms involved in the aberrant
transcriptional rewiring. GSEA identified several inflam-
matory signaling pathways as being significantly induced in
NOX2 KO LSCs relative to controls. These include general
cytokine_cytokine_receptor, interleukin-17 (IL-17)-mediated
signaling, Toll-like receptor signaling, janus kinase signal
transducer and activator of transcription (JAK-STAT) signaling
pathways, and NF-kB target genes, which were all highly
enriched in NOX2 KO LSCs relative to WT controls (Figures
5A–5C and S5A). To confirm these findings, we evaluated
the activation state of components of the NF-kB and JAK-
STAT signaling pathways. Immunoblot analysis revealed
that, at steady state, NOX2 KO leukemia cells have higher
levels of phosphorylated NF-kB and STAT1 (Figure 5D).
Intriguingly, we also observed increased activation of the
stress responsive kinase p38 MAPK as well as its downstream
effector transcription factor, JUN-c, in NOX2 KO leukemia
cells (Figures 5E and 5F). To understand whether NOX2 has
an impact on the ways leukemic cells respond to inflammatory
stimuli, we treated WT and NOX2 KO cells with tumor necrosis
factor alpha (TNF-a) in vitro. Interestingly, in WT leukemia
cells, TNF-a stimulation produced a feedback inhibitory effect
and reduced the activation of inflammatory and stress
signaling pathways. In sharp contrast, NOX2 KO leukemia
cells displayed a severely blunted feedback inhibitory capac-
ity (Figures 5D–5F). Consistent with these findings, in vitro
treatment with TNF-a or Toll-like receptor agonists resulted
in a greater, dose-dependent apoptotic cell death in NOX2
KO leukemia cells compared to WT controls (Figures 5G and
S5B). Thus, NOX2 KO leukemia cells fail to properly regulate
inflammatory cell signaling and as a result exist in a hyperin-
flammatory state and experience chronic cellular stress,
which combined compromises their leukemogenic potential.
The Forkhead Transcription Factor FOXC1 Regulates
Leukemogenesis Downstream of NOX2
Our transcriptional, cell signaling, immunophenotypic, and
morphologic analysis led us to propose that deficiency of NOX2
reprograms key transcriptional networks and forces the differen-
tiation of leukemic blasts. Thus, a fundamental question is
whether transcription factors whose expression is misregulated
as a consequence of NOX2 deficiency could be responsible form cell downregulated genes (left) in NOX2 KO LSCs relative to WT LSCs.
eloid surface antigens Gr1, CD11b, and F4/80 in BM explants of WT and NOX2
alyzed via May-Gr€unwald-Giemsa staining. Additional images are shown in
s Gr1, CD11b, and F4/80 in control and shp22Phox leukemia cells harvested
nalyzed via May-Gr€unwald-Giemsa staining. Additional images are shown in
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Figure 5. NOX2 Regulates Inflammatory Signaling in Leukemic Cells
(A) GSEA showing the enrichment of NF-kB target genes in NOX2 KO LSCs.
(B) GSEA showing the enrichment of components of the JAK-STAT signaling pathway in NOX2 KO LSCs.
(C) GSEA showing the enrichment of components of the Toll-like receptor (TLR) signaling pathway in NOX2 KO LSCs.
(A–C) NES represents the p value and FDR according to Subramanian et al. (2005).
(D) Immunoblot analysis of total and phospho p65(S536), Ikba, and total and phospho STAT1(S727) in WT and NOX2 KO leukemia cells treated with control or
10 ng/mL TNF-a for 30 min. GAPDH was used as a loading control.
(E) Immunoblot analysis of total and phospho p38 MAPK (Thr180/Tyr182) in WT and NOX2 KO leukemia cells treated with control or 10 ng/mL TNF-a for 30 min.
GAPDH was used as a loading control.
(F) Immunoblot analysis of total and phospho c-Jun (S73) inWT andNOX2 KO leukemia cells treated with control or 10 ng/mL TNF-a for 30min. GAPDHwas used
as a loading control.
(G) WT or NOX2 KO cells were cultured in vitro in the presence of increasing doses of TNF-a (left) or lipopolysaccharides (LPSs; right). Cell viability wasmeasured
72 h later with Annexin V, DAPI staining.reversing the developmental arrest enforced by the leukemo-
genic oncogenes. To investigate this, we queried the list of genes
upregulated or repressed in NOX2 KO LSCs and identified candi-
date transcription factors. Among the transcription factors whose
expression is altered, the forkhead family member FOXC1
showed one of the highest-fold repressions, whereas the impor-
tant myeloid differentiation factor CEBPε was among the most
significantly upregulated transcription factor in NOX2 KO LSCs
(Table S1; Figure 4A). Therefore, we evaluated the relative246 Cell Reports 27, 238–254, April 2, 2019expression levels of these two transcription factors in the different
subpopulation of leukemic cells as well as normal hematopoietic
precursors. FOXC1 expression is selectively induced in leukemic
stem cells relative to several primitive normal hematopoietic cells,
suggesting a leukemia specific function. In addition, CEBPε is
also relatively higher in LSCs than in normal undifferentiated
hematopoietic cells, reflecting the myeloid identity of the leuke-
mia cells (Figure S6A). Most importantly, FOXC1 expression is
the highest in the LSC compartment relative to the bulk of
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Figure 6. FOXC1 Regulates Leukemogenesis Downstream of NOX2
(A) Relative mRNA expression level of FOXC1 and CEBPε in the different subpopulations of leukemic cells is shown. LSCs (Sca1+Lin), progenitor (Sca1Lin).
(B) Schematic showing the experimental strategy utilized to study the role of FOXC1.
(C) Flow cytometric plot showing efficient activation of the CRE recombinase activity reporter td-Tomato in 4-OHT-treated CRE-ERT2-expressing leukemic cells
relative to controls.
(D) qRT-PCR based measurement of mRNA expression of the indicated genes in FOXC1 deleted leukemic cells.
(E) The frequency of leukemia cells in the BM of recipients of control or FOXC1-deleted leukemia cells is shown as whiskers minimum-to-maximum plot; the
line inside the box represents the mean, and the top and bottom lines represent the 75% and 25% percentiles. The lines above and below represent SD. n = 10.
*p < 0.05, unpaired Student’s t test.
(F) Weight of spleens (left) and a representative picture of spleens (right) harvested from leukemic mice are shown.
(G) Limiting dilution analysis of control and FOXC1-deleted leukemia cells.
(legend continued on next page)
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leukemic cells, whereas CEBPε is predominantly expressed in
lineage-marker-expressing differentiated leukemic cells (Fig-
ure 6A). Therefore, we hypothesized that in leukemic stem cells,
FOXC1 represses myeloid differentiation downstream of NOX2,
partly through silencing of myeloid-lineage-instructive transcrip-
tional programs.
To directly investigate the role of FOXC1 in leukemic stem
cells, we utilized transgenic mice expressing a floxed allele of
endogenous FOXC1 and a td-Tomato Cre reporter knocked
into the Rosa26 locus (Figures S6B and S6C). We generated pri-
mary leukemia in the FOXC1 floxed background and introduced
tamoxifen-inducible Cre recombinase to assess the impact of
conditional deletion of FOXC1 (Figure 6B). Treatment of leukemic
cells with the synthetic estrogen receptor agonist 4-hydroxy
tamoxifen (4OHT) led to induction of the reporter and resulted
in efficient depletion of FOXC1 mRNA as well as protein levels
(Figures 6C, 6D, and S6D). Moreover, we observed that deletion
of FOXC1 robustly activates CEBPε as well as its known down-
stream target Elane and a number of mature myeloid cell-
specific transcripts similar to what we had observed in NOX2
KO and p22Phox KD LSCs (Figure 6D).
To evaluate the functional role of FOXC1 in the in vivo develop-
ment of leukemia, we transplanted control and FOXC1-deleted
leukemia cells into recipients. Compared to controls, mice trans-
planted with FOXC1-deleted leukemia cells have significantly
lower disease burden and survived relatively longer (Figures
6E, 6F, and S6E). Limiting dilution analysis also revealed that
FOXC1-deleted leukemic cells have a marked reduction in the
frequency of functionally defined LSCs (Figure 6G). Moreover,
transplantation of leukemic cells and the subsequent deletion
of FOXC1 after engraftment also significantly compromised dis-
ease development, suggesting that FOXC1 is crucial for the
engraftment, propagation, and maintenance of leukemic stem
cells in vivo (Figures S6F and S6G). Finally, to investigate
whether FOXC1 contributes to the developmental arrest of
leukemic blasts, we evaluated the immunophenotypic and histo-
logic features of leukemic cells explanted from recipients of con-
trol and FOXC1-deleted leukemia. Our results showed marked
induction of myeloid-maturation-associated surface antigens
and morphologic changes indicative of differentiation (Figures
6H, 6I, and S6H). Collectively, these results argue that FOXC1
is part of the oncogenic transcriptional program operating
downstream of NOX2 that limits the developmental potential of
leukemic stem cells by shutting off myeloid-lineage-specific ge-
netic programs.
NOX2 Is Expressed in Primary Human AMLs, and Its
Suppression Induces Cell Death and Differentiation
Our studies in the genetically definedmurinemodel revealed that
NOX2 is critical for the development and maintenance of
leukemic stem cells. We next wanted to assess the extent to
which NOX2 is involved in the biology of human acute myeloid
leukemia. In order to begin to understand its role, we first evalu-(H) Representative histogram (left) andmean fluorescence intensity of the relative
explants of control and FOXC1-deleted leukemia.
(I) Images showing the morphology of control and FOXC1-deleted leukemia cells
Figure S6H.
248 Cell Reports 27, 238–254, April 2, 2019ated the expression levels of all NADPH-oxidase-related genes,
including the accessory subunits that make up the enzymatic
complex, as well as other related oxido-reductase enzymes
from the acute myeloid leukemia (AML) dataset of The Cancer
Genome Atlas (TCGA) project. NOX2 is by far the predominant
oxidase expressed in AML cells relative to all the other paralogs
and related enzymes (Figure 7A). Moreover, all the necessary
subunits are also sufficiently expressed in leukemic cells. Since
the TCGA data were generated from the transcriptome of unfrac-
tionated bulk leukemic cells, we next assessed the expression of
NOX2 in functionally defined leukemia stem cells (Ho et al.,
2016). In multiple diagnostic specimens of primary human
LSCs, we observed a substantial enrichment of NOX2 tran-
scripts relative to all other family members (Figures 7B and
S7A). Correspondingly, we also observed a similarly high level
of expression for all accessory subunits of the complex, suggest-
ing that human leukemic stem cells are equipped with the full
repertoire of the NOX2 complex.
To study the potential cell-autonomous role of NOX2 in primary
human AML cells, we depleted its expression in vitro using lenti-
viral vectors expressing shRNA constructs. Next, we plated equal
numbers of control and NOX2 KD primary AML cells in the pres-
ence of supportive cytokines (IL-3, stem cell factor [SCF], and
FL3) and followed the in vitro expansion over an extended period
of time. Interestingly, suppression of NOX2 significantly attenu-
ated the in vitro expansion of leukemic cells relative to controls
(Figure 7C). Consistent with these observations, NOX2 KD cells
undergo an increased level of apoptotic cell death relative to con-
trols (Figures 7D and S7B). In addition, treatment with the pan-
NADPH oxidase inhibitor diphenyliodonium (DPI) also led to
significantly reduced viability of leukemic cells, suggesting that
NOX2 potentiates the survival and proliferation of primary human
leukemia cells under in vitro culture conditions (Figure S7C).
Based on the findings from our studies using the murine
model, we hypothesized that NOX2 may also regulate myeloid
differentiation. qRT-PCR-based analysis of gene expression re-
vealed that compared to non-targeted shRNA controls, NOX2
KD AML cells consistently upregulated the myeloid differentia-
tion transcription factor CEBPε as well as the proteolytic
enzymes Elane and CTSG transcripts (Figures 7E and S7D).
More importantly, NOX2 KD AML cells also displayed immuno-
phenotypic and morphologic signs of myeloid differentiation
(Figures 7F, 7G, and S7E). Combined, our results show that
NOX2 controls critical transcriptional programs that mediate
the survival and maintenance of human AML cells in the undiffer-
entiated state.
Suppression of NOX2 Limits the Xenograft Potential of
Primary Human Leukemia Cells
Given the observed effect of in vitro modulation of NOX2 com-
bined with its expression in functionally defined leukemic stem
cells, we hypothesized that NOX2 could potentially have a
functional role in human LSCs. Thus, we performed xenograftexpression levels of the myeloid surface antigens Gr1, CD11b, and F4/80 in BM
analyzed via May-Gr€unwald-Giemsa staining. Additional images are shown in
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experiments using patient-derived primary human AML and
blast crisis chronic myeloid leukemia (CML) specimens to eval-
uate the extent towhich leukemic cells engraft and expand in vivo
after transduction with lentiviral vectors expressing shRNAs
against NOX2. Notably, the percentage of successfully trans-
duced, GFP+ leukemic cells was comparable across experi-
mental groups before transplantation (Figures S7F and S7G).
However, after 8–12 weeks of engraftment, the fraction of total
GFP+ cells as well as the relative engraftment level of the KD
leukemic cells was significantly limited relative to the controls
in all specimens evaluated (Figures 7H–7K, S7F, and S7G).
Therefore, NOX2 plays important functional role in the engraft-
ment, maintenance, and expansion of human primary LSCs.
FOXC1 Is Expressed in a Subset of Primary HumanAMLs
and Regulates Leukemogenesis In Vivo
Our data in the murine model showed that the forkhead family
transcription factor FOXC1 constitutes part of the transcriptional
program operating downstream of NOX2 to regulate the function
of leukemic stem cells. Therefore, we next asked whether
FOXC1 is expressed in immunophenotypically defined primitive
subpopulation of human leukemia specimens. To this end, we
purified the CD34+ fraction of leukemic cells from several pa-
tient-derived specimens as well as normal cord blood and
mobilized adult BM mononuclear cells and performed qRT-
PCR-based gene expression analysis. FOXC1 expression is
minimal in normal hematopoietic precursors and the majority
of leukemic specimens. However, consistent with previous
reports, leukemias harboring mixed lineage leukemia (MLL) rear-
rangement or the translocation t(6:9) expressed high levels of
FOXC1 transcripts (Figure S7H; Table S2) (Somerville et al.,
2015). To test whether the expression of FOXC1 is under the
control of NOX2 in these specimens, we purified CD34+ cells
and transduced with lentiviral shRNA constructs targeting
NOX2. Suppression of NOX2 reduced the expression ofFigure 7. NOX2 and FOXC1 Are Important for the Growth of Primary H
(A) The Cancer Genome Atlas (TCGA) database for AML was used to analyze
accessory subunits (NCF1, NCF2, NCF4, NOXA1, NOXO1, p22Phox, RAC1, and
The reads per kilobase of transcript per million mapped reads (RPKM) values for
(B) RNA-seq analysis was performed on functionally validated leukemic stem cells
Unpublished data are used with permission. Additional supporting data are show
(C) Equal numbers of control or shNOX2-transduced primary AML cells were cultu
percent expansion is reported for each specimen. n = 3, mean ± SD. *p < 0.05; *
(D) Control and shNOX2 primary AML cells were purified and cultured in vitro fo
apoptotic cell death. A representative flow plot (left) and quantitation of 3 technic
(E) The relative expression level of NOX2, CEBPε, Elane, and CTSG is shown in
supporting data are provided in Figure S7D.
(F) Histogram showing the relative expression of the myeloid surface antigen CD
(G) Images showing the morphology of control and NOX2 KD primary AML cells
(H) Relative level of expression of NOX2 is shown in control and shNOX2 primary
(I) Representative flow cytometric plot showing the level of GFP+ (human leukem
recipient mice (left), and quantitation of the relative normalized engraftment, define
(right). Data are shown as whiskers minimum-to-maximum plot; the line inside the
25% percentiles. The lines above and below represent SD. n = 9. ****p < 0.0001
(J) Relative engraftment levels of a bc-CML specimen in which NOX2 is knocked
(K) Relative engraftment levels of an AML specimen in which NOX2 is knocked d
(L) The relative level of expression of FOXC1 is shown in control and shFOXC1 p
(M) Similar analysis as in (I) but performed for FOXC1 knockdown xenografts of
(N) Relative engraftment levels of control and FOXC1 KD groups in an AML spec
(O) Relative engraftment levels of control and FOXC1 KD groups in an additional
250 Cell Reports 27, 238–254, April 2, 2019FOXC1 transcript levels (Figure S7I). Therefore, in at least a sub-
set of human primary AMLs, NOX2 modulates the expression of
FOXC1 at the transcriptional level. Finally, to determine whether
FOXC1 regulates the function of leukemia stem cells in vivo, we
knocked down FOXC1 in a blast crisis CML specimen and
two AML specimens with high expression of FOXC1 and trans-
planted immunocompromised recipient mice. Suppression of
FOXC1 resulted in severely attenuated engraftment of recipient
mice, suggesting that FOXC1 plays key functional role in promot-
ing the growth andmaintenance of primary human LSCs (Figures
7L–7O, S7J, and S7K).
DISCUSSION
Myeloid leukemias arise from hematopoietic precursors through
corruption of genetic programs controlling proliferation, self-
renewal, and myeloid lineage differentiation. Leukemia-initiating
oncogenes often amplify stem cell-associated transcriptional
programs and/or move them outside of their developmental
context to induce a malignant state characterized by the accu-
mulation of undifferentiated precursor cells. Hence, myeloid
leukemias can be viewed as hematologic developmental disor-
ders underwritten by aberrant myeloid cell production. Under-
standing the molecular mechanisms that are either collaborating
with oncogenic programs or suppressed to permit the transfor-
mation of HSPCs and maintenance of leukemia stem cells is
critical in order to design improved therapeutic approaches.
Previous studies have shown that deficiency of the hemato-
poietic oxidase NOX2 causes the expansion of HSPCs and the
overproduction of myeloid cells (Weisser et al., 2016). We
confirmed these findings and also show that NOX2 KO mice
have marked increase in mature myeloid cells in the BM and
PB, suggesting that NOX2 impacts the overall magnitude and
balance of myelopoiesis. Enhanced myelopoiesis is frequently
observed during infection-induced acute inflammation, whereinuman Myeloid Leukemia Cells
the expression levels of several NADPH-dependent oxidases (NOX1–NOX5),
RAC2) as well as related oxido-reductase enzymes (dual-oxidases 1,2, A2).
each gene in a total of 188 AMLs are shown.
isolated from human primary AMLs. The RPKM value for each gene is shown.
n in Figure S7A.
red in vitro in the presence of 10 ng/mL of IL-3, SCF, and FL3, and the relative
*p < 0.01.
r 12 days. Annexin V, DAPI staining was performed to evaluate the degree of
al triplicates (right) are shown. Additional data are shown in Figure S7B.
AML specimens in which NOX2 was knocked down using shRNAs. Additional
11b in control and NOX2 KD primary human AML cells cultured in vitro.
analyzed via May-Gr€unwald-Giemsa staining.
AML cells used in xenograft analysis.
ic cells bearing control or shNOX2) leukemic cells explanted from the BM of
d as (%CD45+GFP+ BM at harvest/% CD45+ GFP+ BM pre-transplant)3 100
box represents the mean, and the top and bottom lines represent the 75% and
, unpaired Student’s t test.
down.
own.
rimary bc-CML specimen used in xenograft analysis.
the bc-CML specimen.
imen expressing high levels of FOXC1.
AML specimen expressing high levels of FOXC1.
hematopoiesis is reconfigured tomeet the demand generated by
the active consumption of mature effector myeloid cells (Taki-
zawa et al., 2017). In light of the hyper-inflammatory state of
NOX2 KO mice, the enhanced myelopoiesis is thus in part a
reflection of the lineage instructive effect of inflammation. Impor-
tantly however, here we provide evidence to show that NOX2
deficiency might also have an additional, cell-intrinsic contribu-
tion to the aberrant hematopoiesis observed in NOX2 KO mice.
In support of this notion, we found that in WT mice under
steady-state conditions, NOX2 expression is most evident in
the myeloid-biased MPP2 and/or MPP3 subpopulations. Strik-
ingly, coincident with this expression pattern, MPP2 and/or
MPP3 subpopulations are the earliest developmentally defined
hematopoietic cells that show significant expansion in NOX2-
deficient mice.
We also observed defects of NOX2 KOBMcells in competitive
repopulation studies, suggesting a potential cell-autonomous
role for NOX2 under regenerative settings. Previous studies
using hematopoietic specific KO of the GTPase RAC2 (an impor-
tant subunit of the NOX2 complex) have also shown similar
phenotypes, including expansion of hematopoietic precursors
and cell-intrinsic regenerative defects (Cancelas et al., 2005;
Roberts et al., 1999; Yang et al., 2007), further underscoring
the potential cell-autonomous role of the NOX2 complex in
HSPCs. The exact mechanism by which the NOX2 complex im-
pacts hematopoiesis is currently unclear. The mechanism
likely involves a complex interplay between cell-autonomous
signaling, heterotypic interactions with the niche, and the influ-
ence of cell-extrinsic inflammatory cues. Therefore, further anal-
ysis using conditional alleles of NOX2 is warranted to elucidate
the underlyingmechanism and parse out the relative contribution
of each to the overall phenotype.
Suppression of NOX2 in a genetically defined aggressive mu-
rine model of blast crisis leukemia led to marked attenuation of
disease development in vivo. Consistent with the well-character-
ized role of NOX2 in redox biology, we observed overall reduc-
tions in the level of ROS in leukemic cells lacking NOX2.
However, our studies revealed that oxidative-stress-related
mechanisms are minimally involved in the leukemic phenotype.
Intriguingly, metabolic characterizations revealed deep impair-
ments in both glycolytic and mitochondrial metabolism of
leukemic cells in the absence of NOX2. Broadly speaking,
deficiency of NOX2 favored fatty-acid-oxidation-dependent
catabolism at the expense of glycolytic metabolism. The exact
mechanism linking NOX2 to changes in tumormetabolism needs
further investigation. Notably, previous reports have shown that
in activated neutrophils, suppression of NOX2 negatively affects
the rate of glycolysis, and under glucose-restricted conditions,
immature neutrophils can burn fatty acids in the mitochondria
to sustain NADPH-dependent ROS production (Baillet et al.,
2017; Griffiths et al., 2017). These findings support the notion
that NADPH oxidase can regulate core metabolic pathways in
myeloid precursor cells. Spin-off reactions utilizing glycolytic in-
termediates provide substrates for building large macromole-
cules necessary for cell growth and therefore NOX2 deficiency
likely engenders a metabolic state less adapted to the require-
ments of a highly proliferative tumorigenic state (Lunt and Vander
Heiden, 2011).Lack of NOX2 effectively collapsed stem cell-associated
genetic programs, depleted functionally defined LSCs, and
reversed the oncogene-induced developmental arrest, allowing
leukemic stem cells to progress to a more mature state mirroring
normal myelopoiesis. Gene expression and biochemical studies
showed that aberrant, hyperinflammatory signaling dominates
the cellular state of NOX2 KO LSCs. Together with the enhanced
myelopoiesis and the hyperinflammatory state observed in non-
leukemic NOX2 KO BM HSPCs, it is tempting to speculate that
deficiency of NOX2 intrinsically promotes inflammatory signaling
and myeloid differentiation in both malignant and non-malignant
settings. Downstream of NOX2, we identified the forkhead family
member transcription factor FOXC1 as part of the mechanism
through which the transcriptional program of LSCs is maintained.
FOXC1 is a critical regulator of early mesodermal development as
well as the function of a number of somatic stem cells (Lay et al.,
2016; Wang et al., 2016; Wilm et al., 2004). In the hematopoietic
system, FOXC1 is expressed not in HSPCs but rather in reticular
mesenchymal cells in the BM niche, and its deletion leads to pro-
found defects in HSC function (Omatsu et al., 2014). Surprisingly,
however, it was recently shown that FOXC1 is ectopically acti-
vated outside of its developmental context in a subset of human
AMLs, and its expression is predominantly associated with the
expression of the HOXA and/or HOXB locus (Somerville et al.,
2015). Notably, leukemic cells in our murine model harbor the
NUP98-HOXA9 translocation, which has previously been shown
to activate the HOXA locus (Shima et al., 2017). Importantly, our
findings here show that the expression of FOXC1 canbemediated
by the activity of theNOX2 complex. Indeed, suppression of either
NOX2 or p22Phox markedly reduced the expression of FOXC1.
In our model, FOXC1 is highly enriched in leukemic stem cells
relative to the bulk leukemia cells and normal HSPCs. Studies in
basal-like breast cancers have also shown that FOXC1 controls
cancer stem cell properties (Han et al., 2015). Coupled with its
function in mesodermal development and somatic stem cells,
these data suggest that FOXC1 broadly maintains a stem cell
genetic program under a multitude of contexts. Genetic deletion
of FOXC1 led to the induction of myeloid differentiation. Notably,
when compared to the differentiation induced by the suppres-
sion of components of the NADPH oxidase complex, which re-
sulted in the accumulation of cells with morphologic features of
granulocytic and monocytic cells, deletion of FOXC1 resulted
primarily in monocytic differentiation, suggesting that it accounts
for part of the mechanism downstream of NOX2. This finding is
consistent with previous reports showing the role of FOXC1 in
monocytic differentiation in AML.
Using the publicly available TCGA dataset and our own patient
samples, we show that NOX2 is the predominant oxidase ex-
pressed in both bulk primary human AML cells and leukemic
stem cells. Similarly, we also showed that FOXC1 is highly
expressed ina subsetofAMLscontaining the leukemogenic trans-
locations t(6:9) and t(11:16) encoding NUP214-DEK and MLL-
CBP, respectively. A recent study has shown that FOXC1 expres-
sion is strongly associated with t(6:9) and the expression of the
HOXA and/or HOXB locus, which is known to be activated in
MLL-rearranged leukemia (Somerville et al., 2015). Genetic sup-
pression of NOX2 in cultured primary human AML cells reduced
the expression of FOXC1, induced the expression of matureCell Reports 27, 238–254, April 2, 2019 251
myeloid cell-function-associated transcripts, and led to terminal
differentiation. More importantly, shRNA-mediated suppression
of eitherNOX2or FOXC1 substantially attenuated the engraftment
potential of primary human leukemia specimens into immunocom-
promised mice. From a clinical point of view, our findings suggest
that inhibitionofNOX2couldpotentially serveasaviable therapeu-
tic approach to induce differentiation of leukemic stem cells.
NADPH oxidases are multimeric enzymes that utilize cofactors
and require complex interactions between subunits for their func-
tion, therebyprovidingnumerousopportunities todesign inhibitory
molecular agents. Indeed, ongoing clinical trials are evaluating
small-molecule inhibitorsofNADPHoxidases for variousdiseases.
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD45R APC-CY7 BD Biosciences 552094
TER119 APC-CY7 BD Biosciences 560509
Gr1 APC-CY7 BD Biosciences 557661
CD11b APC-CY7 BD Biosciences 557657
CD3 APC-CY7 Biolegend 100222
CD19 APC eBiosciences 17-0191-82
CD45R APC eBiosciences 17-0452-82
CD3e PE-CY7 BD Biosciences 552774
CD4 PE-CY7 BD Biosciences 552775
CD8a PE-CY7 BD Biosciences 552877
CD45 A700 BD Biosciences 560566
CD34 PE-CY7 BD Biosciences 348791
CD11b APC BD Biosciences 340546
Lineage cocktail FITC BD Biosciences 340937
Bacterial and Virus Strains
Max efficiency DH5alpha competent cells ThermoFisher 18258012
Biological Samples
Human Cord blood samples University of Colorado Hospital N/A
Mobilized adult BM mononuclear cells University of Colorado Hospital N/A
Primary AML samples University of Colorado Hospital N/A
Chemicals, Peptides, and Recombinant Proteins
APOCYNIN Sigma-Aldrich 178385
DPI Sigma-Aldrich 43088
Cell-ROX deep red Life technologies C10422
dsTat-Scramble Ana-spec AS-63821
dsTat-gp91 Ana-spec AS-63821
4-OHT Sigma-Aldrich H7904
Tamoxifen MP Biomedical 0215673883
Rotenon Sigma-Aldrich R8875
Oligomycin A Sigma-Aldrich 871744
Antimycin Sigma-Aldrich A8774
RIPA lysis buffer Thermo Fisher 89900
Halt Protease inhibitor Thermo Fisher 87785
Laemmli sample buffer BioRad 1610737
FCCP Sigma-Aldrich C2920
May-Grunwald stain Sigma-Aldrich MG500
Geimsa stain Sigma-Aldrich GS500
Palmitic Acid, [9,10-3H(N)]-, 1mCi (37MBq) Radiolabeled PerkinElmer NET043001MC
Palmitic Acid Sigma-Aldrich P0500-100G
Deposited Data
RNaseq of WT and NOX2 KO LSCs This paper GEO: GSE117657
Experimental Models: Cell Lines
293FT Cell Line ThermoFisher R70007
Platinum-E (Plat-E) retroviral packaging cells Cell Biolabs, Inc RV-101
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REAGENT or RESOURCE SOURCE IDENTIFIER
Experimental Models: Organisms/Strains
B6.SJL-Ptprca Pepcb/BoyJ (CD45.1) mice Craig Jordan Lab N/A
C57BL/6J (CD45.2) mice The Jackson Laboratory 000664
B6.129S-Cybbtm1Din/J i.e., NOX2 KO mice Generous gift from Dr Eric Campbell
and Dr. Lucy Gold lab
N/A
FOXC1 f/f; Ai14 Provided by Dr. Julie Siegenthaler lab N/A
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ Craig Jordan Lab N/A
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ Craig Jordan Lab N/A
Oligonucleotides
Please refer to Table S3 N/A
Recombinant DNA
PLKO.1 GFP Craig Jordan Lab N/A
pPax2 Craig Jordan Lab N/A
pMD2 Craig Jordan Lab N/A
MSCV-p210BCR-ABL-IRES-GFP Craig Jordan Lab N/A
MSCV-NUP98-HOXA9-IRES-YFP Craig Jordan Lab N/A
MSCV-CRE-ERT2-PURO Addgene 22776 (Kumar et al., 2009)
MSCV-PURO Dr. Patricia Ernst lab N/A
PLKO.1-shNT-Puro CU genomics core N/A
PLKO.1-shp22phox-Puro CU genomics core N/A
PLKO.1-shNT-GFP This paper N/A
PLKO.1-shNOX2#1-GFP This paper N/A
PLKO.1-shNOX2#2-GFP This paper N/A
PLKO.1-shFOXC1-GFP This paper N/A
Software and Algorithms
Graphpad Prism 6 https://www.graphpad.com Version 6
FlowJo https://www.flowjo.com/ Version 10
Other
CD34+ MicrobeadKit Miltenyi Biotec 130-056-702
LS Columns Miltenyi Biotec 130-042-401
Ficoll Paque GE Healthcare GE17-1440-02CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Craig T.
Jordan (Craig.jordan@ucdenver.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
MICE
Mice were housed in a pathogen free facility with strict adherence to The Recommended Guide for Care and Use of Laboratory
Animals issued by the National Institutes of Health and animal protocols approved by the Institutional Animal Care and Use
Committee at The University of Colorado school of medicine (IACUC). In each experiment, age of mice was balanced with maximum
2 weeks of difference between the experimental and control group.
FOXC1 F/F AI14-FLOX MICE
Heterozygous Foxc1-flox (Sasman et al., 2012); Ai14-flox (Jackson Laboratory stock number 007914) animals were crossed to
generate Foxc1 floxed animals for this study.e2 Cell Reports 27, 238–254.e1–e6, April 2, 2019
PRIMARY AML XENOGRAFT STUDIES
NOD.Cg-Prkdcscid Il2rgtm1Wjl Tg(CMV-IL3,CSF2,KITLG)1Eav/MloySzJ(NSGS) mice originally purchased from Jackson laboratory
(stock number 013062) and subsequently bred at the university of Colorado school of medicine animal facility, were conditioned
24 hours prior to transplant with 25 mg/kg busulfan via intra-peritoneal (IP) injection. Primary AML cells were infected with shRNA
lentivirus 24 hours prior to transplant and injected via tail vein at a concentration of 2.0 e6 cells in 0.1ml saline per recipient mouse.
A small fraction of the infection reaction is kept for additional 24 hours to determine the transduction efficiency. For all experiments,
8-12 mice were injected per experimental group. Engrafted mice were sacrificed after 8-12 weeks at which point, we typically
observed > 15% leukemia in the BM.
PRIMARY HUMAN LEUKEMIA SPECIMENS
Primary human AML specimens were obtained from apheresis product, PB, or BM of AML patients who gave informed consent for
sample procurement on the University of Colorado tissue procurement protocols. See Table S2 for additional details regarding sex,
age and disease relevant information on human specimens used in the current study. The selection of particular specimens is based
solely on the amenability of the samples for experimental procedures including in vitro culture studies, lentiviral infection and
engraftment into immune compromised mice.
PRIMARY AML CELL CULTURE AND MEDIA
Primary human AML cells were resuspended at about 100-200 e6 cells per ml in freezing media composed of 50% FBS (GE Health-
care), 10% DMSO (Sigma) and 40% IMDM media (GIBCO) and then cryo-preserved in liquid nitrogen. Cells were thawed in 37C
water bath, washed twice in thawing media composed of IMDM (GIBCO), 2.5% FBS (GE Healthcare) and 10 ug/ml DNase (Sigma).
Cells were cultured in base (IMDM+10%FBS) or cytokine supplemented media (IMDM, 10%FBS, 10ng/ml of IL3, SCF & FL3 from
PeproTech) in 37C, 5% CO2 incubator.
HUMAN CORD BLOOD SAMPLES
Cord blood was obtained from healthy full-term pregnancies after informed consent in accordance with the Declaration of Helsinki
from University of Colorado Hospital at Aurora. Initially, cord blood volume and cell counts were measured and then diluted 1:1 with
PBS+ 2mM EDTA+0.5% BSA. Maximum 30mL of diluted cord blood was carefully layered on 15 mL of Ficoll Paque in a 50ml falcon
tube and centrifuged for 20minutes, 800 g, without brakes. Middle (buffy coat) layer containingmononuclear cells was harvested and
diluted 1:1 with PBS 2mM EDTA 0.5% BSA and then centrifuged for 5 minutes at 800 g. Cell pellets were collected and washed with
PBS 2mM EDTA 0.5% BSA and centrifuged for 10 minutes at 200 g. Immunomagnetic labeling and separation were performed
according to the manufacturer’s manual of the CD34 MicroBead Kit, human (Miltenyi Biotec). Cells were either used immediately
for experiments or frozen in Cryostor CS10.
CELL LINES
293FT and the 293 derivative Platinum-E cells were cultured in DMEM +1% P/S + 10% heat-inactivated FCS and used for lentiviral
and retroviral packaging respectively.
METHOD DETAILS
BM cell isolation
Micewere euthanized by CO2 asphyxiation followed by cervical dislocation. Tibia and femur bones were isolated and kept in ice-cold
FACS buffer (DPBS, 2% heat inactivated fetal bovine serum). BM was flushed out using 1ml syringe fitted with 26G needle directly
into 2mls of ice-cold FACS buffer in a FACS tube. BM clumps were broken up by pipetting repeatedly and centrifuged briefly. Cell
pellets were re-suspended in 1mL of 1x RBC lysis buffer and centrifuged for 2minutes. RBC lysed cell pellets werewashed oneswith
FACS buffer, resuspended in 2mls of FACS buffer and passed through filter cap fitted FACS tubes (BD Bioscience). An aliquot of this
single cell suspension was used for flow cytometric analysis.
PB isolation
100-200ul of PBwas collected frommice directly into heparin-coated collection tubes by small puncture of the submandibular plexus
vein with a 26 Gauge needle. Unclotted blood was transferred into 1.5 mL Eppendorf microfuge tubes containing 300ul of a
1:1 volume mixture of 2% dextran and Heparin sulfate solution. The mixture was vortexed and allowed to settle for 20 minutes.
The upper, relatively clear layer containing mononuclear cells was transferred into narrow bottom FACS tubes and washed ones
with 1 mL of ice-cold FACS buffer. Cells were RBC lysed as described above and washed one more time with FACS buffer before
use for staining and flow cytometric analysis.
PB differential cell count
20ul of uncoagulated PBwas allowed tomigrate into capillary tubes, which were then inserted into the chamber of the HemaTrue differ-
ential cell count analyzer (HESKA). Three independent measurements were taken for eachmouse and the average count was reported.Cell Reports 27, 238–254.e1–e6, April 2, 2019 e3
Flow Cytometric Analysis and Cell Sorting
BM and PB cells were stained with the appropriate antibodies (See key resources table above) for 30 minutes on ice in FACS buffer.
Details of antibody combinations used to identify each population are given in the figure legends. After staining, cells were washed
ones with ice-cold FACS buffer. Dead cells and cellular debris were excluded from the analysis using 4,6, diamino-2-phenylidole
(DAPI) staining. A FACSAria II (BD) instrument was used for analysis and cell sorting. Cell purity was checked after each sort and
generally ranged 96%–100%. Flow Cytometry data was visualized during collection via FACS Diva software (BD) and subsequently
analyzed using FlowJo10 software.
RT-QPCR Analysis
Cells collected from the sorter were washed ones with ice-cold FACS buffer and either used immediately or flash frozen and subse-
quently used for RNA extraction. RNA from small number of cells was isolated using the RNeasy Micro kit (QIAGEN) following the
manufacturers instruction. On column Dnase digestion was performed to eliminate contamination with genomic DNA. RNA was
quantified using Nanodrop spectrophotometer (Fisher Thermo scientific) and was subsequently revers transcribed into cDNA using
the qScript cDNA synthesis kit (QuantaBio). cDNA was ultimately used for Quantitative Real-Time PCR analysis on LightCycler96
Real-Time PCR system using SYBR Green I Master Mix reagent (Roche). QPCR primers are listed in key resources Table above.
Retroviral Oncogenesis
Retroviral Mouse stem cell virus (MSCV) based plasmid vectors expressing BCR-ABL and NUP98-HOXA9 were transfected into the
packaging cell line Platinum-E (a 293T derivative expressing viral structure proteins downstream of the EF1a promoter). Calcium
phosphate solution containing HEPES buffered saline (HBS) and Calcium Chloride was used to transfect 30ug of the plasmid
DNA into the packaging cells. High titer virus was harvested 48 hours after transfection, filtered, flash frozen and stored in liquid
nitrogen. 24 hours before infection, BM cells were harvested from donor mice (Age and sex matched WT and NOX2 KO or
FOXC1 f/f; Ai14 mice) and the undifferentiated Lin– cells were sorted by flow cytometry and were cultured overnight in LSK media
(IMDM, 10ng/ml IL3, 10ng/ml IL6 and 50ng/ml SCF). The next day 0.75 mL of each virus (BCR-ABL, NUP98-HOXA9) was added
to 0.5 3 106 cells re-suspended in 1 mL of 2x LSK media with 16ug polybrene. The infection was repeated 1 more time 8 hours
later. Infection efficiency was determined, and equal number of total and leukemic cells were transplanted retroorbitally into
unconditioned, syngeneic recipient mice. For secondary transplantation, BCR-ABL and NUP98-HOXA9 double positive leukemic
cells were sorted from BM explants of primary recipients and equal numbers of these leukemic cells were injected into secondary
recipient mice.
Murine leukemia transplantation
For primary and secondary leukemia transplantation (Figures 2C and 2D) 10,000 leukemic cells were mixed with 100,000 normal
carrier BM cells retroorbitally into 8-12 weeks old female C57B/6 recipient mice. 14 days post transplantation, leukemic mice
were sacked and spleen as well as BM cells were isolated as described above. For survival analysis, moribund mice were sacked
(at variable time points) and the presence of leukemia cells was determined via flow cytometry by harvesting BM and spleen cells.
For limit dilution analysis (Figure 2F), The indicated number of LSCs were sorted and mixed with 100,000 normal carrier cells and
transplanted retro-orbitally into 8-12 weeks old female C57B/6 recipient mice. 14 days post transplantation, recipient mice were
sacked, and the spleen and BM were analyzed for the presence or absence of leukemia via flow cytometry.
shRNA mediated suppression of p22Phox expression
Primary leukemia cells were harvested from the BM of recipients of WT in vitro transformed leukemia cells. Leukemic cells were then
FACS purified and transduced with a lentiviral vector in a PLKO.1-Puro backbone expressing an shRNA against CYBA (the gene
encoding the p22Phox subunit of the NADPH oxidase complex) for 48 hr. Next, we performed puromycin selection for 72 hours
at a dose of 3ug/ml. We cultured cells for an additional 24 hr in fresh media without puromycin. Live cells were sorted, counted
and transplanted into secondary recipients at an equal dose of 40,000 cells per mouse. 14 days post transplantation, recipient
mice were taken down and disease burden was assessed in the BM and spleen.
Metabolomics
Approximately 4x10^ 5 leukemia cells were sorted, and metabolomics analyses were performed via ultra-high pressure-liquid chro-
matography-mass spectrometry (UHPLC-MS – Vanquish and Q Exactive, Thermo Fisher) as previously reported (Nemkov et al.
2017). Briefly, cells were extracted in ice cold methanol:acetonitrile:water (5:3:2 v/v) at a concentration of 1 million cells/ml of buffer.
After vortexing for 30 min at 4C, samples were centrifuged at 15,000 g for 10 min at 4C and supernatants processed for metabo-
lomics analyses. Ten microliters of sample extracts were loaded onto a Kinetex XB-C18 column (150 3 2.1 mm i.d., 1.7 mm –
Phenomenex). A 3 min isocratic run (5% B) and a 9 min gradient from 5%–95% B (phase A: water and B: acetonitrile with + 0.1%
formic acid for positive ion mode or with 10 mM ammonium acetate for negative ion mode) were used to elute metabolites. The
mass spectrometer scanned in Full MS mode (3 min method) or performed acquisition independent fragmentation (AIF - MS/MS
analysis – 9minmethod) at 70,000 resolution in the 70-900m/z range, 4 kV spray voltage, 15 sheath gas and 5 auxiliary gas, operatede4 Cell Reports 27, 238–254.e1–e6, April 2, 2019
in negative and then positive ion mode (separate runs). Metabolite assignment was performed against an in-house standard library,
as reported (Nemkov et al., 2017). Metabolite levels were then normalized to protein quantification.
Seahorse Assays
XF96 (Agilent Technologies, 102417-100) extracellular flux assay kits were used to measure oxygen consumption (OCR) and glyco-
lytic flux (ECAR). Cells were sorted, and directly plated in a XF96 cell culture microplate. OCR and ECAR was measured according to
the manufacture protocol and as previously described (Lagadinou et al., 2013). Briefly, five replicate wells of 1 3 105 cells were
seeded in a Cell-Tak (Corning, 324240) coated 96-well XF96 well plate. Thirty minutes prior to analysis, the medium was replaced
with Seahorse XF media (Agilent Technologies, 102353-100) and the plate was incubated at 37C. Analyses were performed both
at basal conditions and after injection of 5 mg/ml oligomycin (Sigma-Aldrich, 871744), 2 mM FCCP (Sigma-Aldrich, C2920), 5 mM
Antimycin A (Sigma-Aldrich, A8774), and 5 mM rotenone (Sigma-Aldrich, R8875).
FAO assay
FAO assay was performed as described previously (Ye et al., 2016). Briefly, sorted Lin– WT and NOX2 KO leukemia cells were
cultured in IMDM containing 10 mM palmitate (Sigma) and 10% FBS (Thermo Scientific) overnight and then equal numbers of cells
were plated in 48-well plates supplemented with FAO assaymedium (IMDMcontaining 2.5% FBS, 10 mMpalmitic acid, 1% fatty acid
free BSA (Sigma), 500 mM carnitine (Sigma). Cells were pulsed for 4 hours with 0.5 mCi [9,10-3H(N)]-palmitic acid (Perkinelmer) and
the medium was collected to analyze the released 3H2O, formed during cellular oxidation of [3H] palmitate. Briefly, medium was
precipitated by 10% trichloroacetic acid (Sigma) and then supernatant was neutralized with 6N NaOH (Sigma) and loaded into ion
exchange columns packed with DOWEX 1X2-400 resin (Sigma). The radioactive product was eluted with water and quantitated
by liquid scintillation counting.
In vitro drug treatment
Apocynin (sigma-Aldrich) was dissolved in DMSO for a final stock concentration of 10mM. Leukemic cells were cultured in vitro
and treated with 1-100uM doses for 24 hours. The short peptides, Gp91 ds-tat and Scramble ds-tat (Ana-Spec) were dissolved
in DMSO at a final stock concentration of 100mM. 0.5 to 50uM doses of each was added into cultured leukemic cells for
3-24 hours.
RNA-Seq: Sample preparation and data analysis
Sca1+Lin– LSCs from the BM of secondary recipients were sorted. A total of 4 mice BM were pooled for each replicate sample used
for the analysis. Sort purity was > 98%. Total RNAwas extracted using the RNeasyMicro kit (QIAGENE). The total RNA concentration
was determined with the NanopDrop 1000 spectrophotometer (NanoDrop) and RNA quality assessed with the Agilent Bioanalyzer
(Agilent). The TruSeq StrandedmRNASample Preparation Kit (Illumina) was used for next generation sequencing library construction
permanufacturer’s protocols. Briefly, mRNAwas purified from 200ng total RNAwith oligo-dTmagnetic beads and fragmented. First-
strand cDNA synthesis was performed with random hexamer priming followed by second-strand cDNA synthesis using dUTP incor-
poration for strand marking. End repair and 30-adenylation was then performed on the double stranded cDNA. Illumina
adaptors were ligated to both ends of the cDNA, purified by gel electrophoresis and amplified with PCR primers specific to the
adaptor sequences to generate cDNA amplicons of approximately 200-500bp in size. The amplified libraries were hybridized to
the Illumina single end flow cell and amplified using the cBot (Illumina). Single end reads of 100nt were generated for each sample
using Illumina’s HiSeq2500v4. Raw reads generated from Illumina HiSeq2500 sequencing were de-multiplexed using
bcl2fastq version 1.8.4. Quality filtering and adaptor removal were performed using Trimmomatic version 0.32 with the following
parameters’’:SLIDINGWINDOW:4:20TRAILING:13LEADING:13ILLUMINACLIP:adapters.fasta:2:30:10 MINLEN:25.’’ Processed/
cleaned reads were then mapped to the reference sequence using the SHRiMP version 2.2.3 alignment software given the following
parameters: ‘‘–qv-offset 33–all-contigs.’’ Differential expression analyses and data normalization were performed using the
CuffDiff tool from the cufflinks version 2.0.2 package given the following parameters: ‘‘–FDR 0.05 -u -b GENOME.’’
GSEA analysis
GSEA analysis was performed using GSEA version 3.0 (Broad institute). FPKM values produced from CuffDiff analysis were
formatted into GCT files containing expression values for genes in different biological states. CLS files were manually built to label
biological states involved in each study. When performing GSEA analysis, several gene set databases were used including:
c2.cp.kegg.v6.0.symbols.gmt, c2.cp.reactome.v6.0.symbols.gmt and an in-house database containing a collection of 860 gene
sets of our interest. Following parameters were used: Number of permutations = 1000, permutation type = gene_set, chip platform =
annotations_ALL.zip. Other parameters were left at default values.
May-Grunwald Geimsa stain
Cells were cyto-spun onto glass slides at about 0.1e6 concentration per spot at 600RPM for 4minutes and air-dried for 10minutes at
room temprature. Slides were then stained in May-Gr€unwald Stain (Sigma) for 5 minutes, followed by a 1.5 minute rinse in Phosphate
buffer (sigma). Slides were placed for 20 minutes in Geimsa solution (Sigma) diluted 1:20 with DI water and rinsed for 2 minutes inCell Reports 27, 238–254.e1–e6, April 2, 2019 e5
DI water. After staining, cells were dried at room temperature, mounted in Cytoseal 60 (Thermo Scientific) and submitted for imaging
on Zeiss AX10 microscope.
In vitro 4OHT and in vivo Tamoxifen treatment
4 Hydroxy-Tamoxifen (Sigma-Aldrich) was dissolved in 100% Ethanol for a stock concentration of 25mM. Cultured leukemic cells
were treated with a final concentration of 250nM for 24 hours, washed with FACS buffer and re-plated. For in vivo use, Tamoxifen
(MP Biomedical) was dissolved in Sunflower oil with 2ul 100% Ethanol per mg of Tamoxifen for a stock concentration of
20mg/ml. 200ul of the stock was injected for a final dose of 4mg into the intra-peritoneal cavity of leukemic mice using a 26-gauge
needle.
Protein lysates preparation and WB
Cells were harvested and washed twice in ice cold PBS (0.5% FBS) and resuspended in RIPA lysis and extraction buffer (Thermos
Fisher) supplemented with Protease and phosphatase inhibitor cocktail (Thermo fisher) at a concentration of 1xe6 cells per 150 ul.
The suspension was incubated on ice for 15minutes with gentle rocking and centrifuged at 14000 RPM for 15minutes. 120 ul of clear
lysates were transferred to new tubes into which 60 ul of Lammli sample buffer (biorad) was added. Tubes were vortexed briefly and
boiled at 95 degrees for 10 minutes. For WB analysis, samples were loaded and resolved on 4 - 15% SDS-PAGE precast gels
(biorad), transferred to PVDF membranes, blocked in 5% milk in TBS with 0.1% Triton X-100 (Sigma) for 1 hr. After blocking, the
PVDF membranes were rinsed briefly with TBST and incubated with primary antibodies diluted in 5% BSA/TBST at 4C overnight,
washed (5 times 10 minutes each), incubated with secondary antibodies at room temperature for 1 hour at 1:10,000 dilution and
washed again and finally subjected to imaging. The WB results were imaged on the ChemiDoc Imaging System (Biorad) and visual-
ized in the Image Lab software (BIO-RAD).
shRNA and lentiviral production
shRNA sequences were constructed into pLKO.1-GFP, which contain a human U6 promoter to drive shRNA expression and a human
PGK promoter to drive GFP expression to label shRNA-expressing cells. The detailed methods for generating lentiviral particles, and
infecting AML cells are described here (Ashton et al., 2012). Briefly, each pLKO.1-shRNA construct was co-transfected with pPax2
(provides packaging proteins) and pMD2.G (provides VSV-g envelope protein) plasmids into 293T cells (System Bioscience) to
produce lentiviral particles. At about 48 hours post transfection, 293T culture supernatants containing lentiviral particles were
harvested, filtered, aliquoted and stored in80C freezer for future use. At the day of infection, these lentivirus aliquots were thawed
and used to infect cells. Primary AML cell were cultured for 3 hours in cytokine supplemented media and were typically infected by
mixing 5 e6 cells with 1ml of freshly thawed lentivirus and Polybrene at a final concentration of 8 ug/ml in a 12 well tissue culture
plate. At 3-6 days post infection, GFP-positive cells were sorted and analyzed. shRNA targeting sequences are listed in key resources
table above.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical details for each experiment are indicated in the legend of each figure, where appropriate. The sample size used in each
experiment was not predetermined or formally justified for statistical power. In general, for samples with low variation, 3-5 samples
per condition were analyzed in each experiment. For samples with larger variation, for instance transplantation experiments,
generally 8-12 samples per condition were analyzed in each experiment. Unpaired Student’s t test was used to determine signifi-
cance; P values less than 0.05 were considered significant.
DATA AND SOFTWARE AVAILABILITY
The accession number for the RNA-Seq data reported in this paper is GEO: GSE117657.e6 Cell Reports 27, 238–254.e1–e6, April 2, 2019
